

EAU-ESMO Consensus Statements on the Management of Prostate Cancer – An International Collaborative Multistakeholder

European Urology

77, 223-250

DOI: [10.1016/j.eururo.2019.09.035](https://doi.org/10.1016/j.eururo.2019.09.035)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. <i>European Urology Focus</i> , 2021, 7, 1067-1074. | 1.6 | 7 |
| 2 | Nested Variant Urothelial Carcinoma of the Bladder. <i>Urology</i> , 2020, 144, 9-12. | 0.5 | 2 |
| 3 | The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review. <i>Progres En Urologie</i> , 2020, 30, 322-331. | 0.3 | 7 |
| 4 | Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7268. | 1.8 | 33 |
| 5 | Endoscopic Molecular Imaging plus Photoimmunotherapy: A New Strategy for Monitoring and Treatment of Bladder Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 409-418. | 2.0 | 3 |
| 6 | Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2021, 39, 1757-1768. | 1.2 | 20 |
| 7 | Optimizing frontline therapy in advanced urothelial cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 983-985. | 0.6 | 3 |
| 8 | Review: Brain Metastases in Bladder Cancer. <i>Bladder Cancer</i> , 2020, 6, 237-248. | 0.2 | 4 |
| 9 | From Basic Science to Clinical Research to Develop New Solutions to Improve Diagnoses and Treatment of Bladder Cancer Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2373. | 1.0 | 1 |
| 10 | The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 565086. | 1.3 | 20 |
| 11 | A prospective comparative study of routine versus deferred pelvic drain placement after radical prostatectomy: impact on complications and opioid use. <i>World Journal of Urology</i> , 2021, 39, 1845-1851. | 1.2 | 3 |
| 12 | Gender discrepancies in bladder cancer: potential explanations. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 841-849. | 1.1 | 17 |
| 13 | Variant histology in bladder cancer: diagnostic and clinical implications. <i>Translational Cancer Research</i> , 2020, 9, 6565-6575. | 0.4 | 23 |
| 14 | Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic – Rapid Review. <i>Clinical Oncology</i> , 2020, 32, 347-353. | 0.6 | 10 |
| 15 | Cutting-edge Management of Muscle-invasive Bladder Cancer in 2020 and a Glimpse into the Future. <i>European Urology Oncology</i> , 2020, 3, 789-801. | 2.6 | 3 |
| 16 | Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives. <i>European Urology Focus</i> , 2020, 6, 632-638. | 1.6 | 30 |
| 17 | Ureteral and urethral recurrence after radical cystectomy: a systematic review. <i>Current Opinion in Urology</i> , 2020, 30, 441-448. | 0.9 | 10 |
| 18 | Transurethral resection of bladder tumor and the need for re-transurethral resection of bladder tumor. <i>Current Opinion in Urology</i> , 2020, 30, 370-376. | 0.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. <i>European Urology</i> , 2021, 79, 82-104. | 0.9 | 1,152 |
| 20 | Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach. <i>European Radiology</i> , 2021, 31, 3874-3883. | 2.3 | 34 |
| 21 | Stage T1 bladder cancer: diagnostic criteria and pitfalls. <i>Pathology</i> , 2021, 53, 67-85. | 0.3 | 11 |
| 22 | Frailty impact on postoperative complications and early mortality rates in patients undergoing radical cystectomy for bladder cancer: a systematic review. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 9-23. | 0.7 | 22 |
| 23 | Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes. <i>Pathology</i> , 2021, 53, 56-66. | 0.3 | 22 |
| 24 | Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 144-154. | 0.9 | 13 |
| 25 | Re: J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. <i>Eur Urol</i> 2021;79:82-104. <i>European Urology</i> , 2021, 79, e30-e32. | 0.9 | 5 |
| 26 | The role of palliative radiotherapy in the management of elderly and frail patients with advanced bladder cancer: A survey by the AIROuro-group. <i>Medical Oncology</i> , 2021, 38, 14. | 1.2 | 0 |
| 27 | Bladder cancer: what's new in 2019-2020. <i>Onkourologiya</i> , 2021, 16, 147-154. | 0.1 | 0 |
| 28 | Imaging and Management of Bladder Cancer. <i>Cancers</i> , 2021, 13, 1396. | 1.7 | 30 |
| 29 | Prognostic Value of an Immunohistochemical Signature in Patients With Bladder Cancer Undergoing Radical Cystectomy. <i>Frontiers in Oncology</i> , 2021, 11, 641385. | 1.3 | 1 |
| 30 | En Bloc Tumor Resection, Optical Molecular Imaging, and the Potential Synergy of the Combination of the Two Techniques in Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 638083. | 1.3 | 3 |
| 31 | Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 180-190. | 0.8 | 10 |
| 32 | Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes. <i>European Urology</i> , 2021, 79, 621-632. | 0.9 | 77 |
| 33 | Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder. <i>Cancers</i> , 2021, 13, 2377. | 1.7 | 4 |
| 34 | Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients. <i>Cancers</i> , 2021, 13, 2327. | 1.7 | 8 |
| 35 | Single staff cystectomy in a low-volume center: Oncological outcomes and complications. <i>Canadian Urological Association Journal</i> , 2021, 15, E582-E587. | 0.3 | 1 |
| 36 | A Potential Role for HUWE1 in Modulating Cisplatin Sensitivity. <i>Cells</i> , 2021, 10, 1262. | 1.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Berberine suppresses bladder cancer cell proliferation by inhibiting JAK1-STAT3 signaling via upregulation of miR-17-5p. <i>Biochemical Pharmacology</i> , 2021, 188, 114575. | 2.0 | 19 |
| 38 | Current Perioperative Therapy for Muscle Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 495-511. | 0.9 | 2 |
| 39 | Molecular pathology of urothelial carcinoma. <i>Human Pathology</i> , 2021, 113, 67-83. | 1.1 | 24 |
| 40 | Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. <i>European Urology Focus</i> , 2022, 8, 1270-1277. | 1.6 | 11 |
| 41 | Prediction of Bladder Cancer Treatment Side Effects Using an Ontology-Based Reasoning for Enhanced Patient Health Safety. <i>Informatics</i> , 2021, 8, 55. | 2.4 | 3 |
| 42 | Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 471-479. | 0.8 | 7 |
| 43 | Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies. <i>World Journal of Urology</i> , 2022, 40, 915-927. | 1.2 | 8 |
| 44 | Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study. <i>European Urology Focus</i> , 2022, 8, 995-1002. | 1.6 | 6 |
| 45 | Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. <i>Molecular Carcinogenesis</i> , 2022, 61, 5-18. | 1.3 | 6 |
| 46 | Emerging diagnostic and therapeutic strategies for urothelial carcinoma. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 1-1. | 0.7 | 1 |
| 47 | Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells. <i>International Journal of Biological Sciences</i> , 2021, 17, 3456-3475. | 2.6 | 14 |
| 48 | Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials. <i>Seminars in Oncology</i> , 2021, 48, 181-192. | 0.8 | 2 |
| 50 | Intravesical <i>Pseudomonas aeruginosa</i> mannose-sensitive Hemagglutinin vaccine triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1507-1517. | 2.0 | 11 |
| 51 | Consensus statements from the EAU-ESMO collaboration for advanced and variant bladder cancer: can we move the needle to improve survival?. <i>Translational Andrology and Urology</i> , 2020, 9, 2488-2492. | 0.6 | 1 |
| 52 | Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime?. <i>Translational Andrology and Urology</i> , 2020, 9, 2479-2482. | 0.6 | 1 |
| 53 | The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2022, 81, 95-103. | 0.9 | 158 |
| 54 | European Association of Urology Section of Urolithiasis and International Alliance of Urolithiasis Joint Consensus on Retrograde Intrarenal Surgery for the Management of Renal Stones. <i>European Urology Focus</i> , 2022, 8, 1461-1468. | 1.6 | 23 |
| 55 | A classification based on tumor-stroma ratio and tumor budding for patients with muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 323-330. | 1.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 56 | Trends and Predictors of Hypofractionated and Intensity-Modulated Radiotherapy for Organ Preservation in Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e94-e103. | 0.9 | 1 |
| 57 | Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103570. | 2.0 | 11 |
| 58 | Combination of histological and molecular data for improving outcome prediction in non-muscle invasive bladder cancerâ€”narrative review. <i>Translational Cancer Research</i> , 2020, 9, 7323-7336. | 0.4 | 1 |
| 60 | PET/CT in Bladder Cancer: An Update. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 475-485. | 2.5 | 14 |
| 61 | Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group. <i>Cancers</i> , 2022, 14, 1130. | 1.7 | 4 |
| 62 | Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration. <i>World Journal of Urology</i> , 2022, 40, 1167-1174. | 1.2 | 9 |
| 64 | Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology â€” Young Academic Urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 195.e27-195.e35. | 0.8 | 5 |
| 65 | A Personalized Approach to Radical Cystectomy Can Decrease Its Complication Rates. <i>Journal of Personalized Medicine</i> , 2022, 12, 281. | 1.1 | 2 |
| 66 | E-cadherin expressions on bladder and its association with cancer progressivity: a retrospective cohort study. <i>African Journal of Urology</i> , 2022, 28, . | 0.1 | 1 |
| 67 | Prognostic impact of insulinâ€™like growth factorâ€™ and its binding proteins, insulinâ€™like growth factorâ€™ binding proteinâ€™2 and â€™3, on adverse histopathological features and survival outcomes after radical cystectomy. <i>International Journal of Urology</i> , 2022, , . | 0.5 | 3 |
| 68 | Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e346-e352. | 0.9 | 5 |
| 69 | Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis. <i>British Journal of Cancer</i> , 2022, 127, 313-320. | 2.9 | 13 |
| 70 | Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4969. | 1.8 | 5 |
| 71 | Impact of Adjuvant Chemotherapy on Variant Histology of Upper Tract Urothelial Carcinoma: A Propensity Score-Matched Cohort Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 843715. | 1.3 | 3 |
| 72 | Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. <i>European Urology</i> , 2022, 82, 273-279. | 0.9 | 29 |
| 73 | How do endoscopic bladder tumor resection techniques affect pathology practice? EAU Section of Uro-Technology (ESUT) and Uropathology (ESUP) survey. <i>World Journal of Urology</i> , 2022, , . | 1.2 | 1 |
| 74 | <sc>PDâ€™L1</sc> expression and <sc>FGFR</sc>â€™mutations among Danish patients diagnosed with metastatic urothelial carcinoma: A retrospective and descriptive study. <i>Apmis</i> , 2022, 130, 498-506. | 0.9 | 2 |
| 75 | Robot-Assisted Laparoscopic Radical Cystectomy and Modified Y-Shaped Ileal Orthotopic Neobladder Reconstruction. <i>Frontiers in Surgery</i> , 2022, 9, . | 0.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 76 | Tumors of the Urinary Bladder. , 2021, , 345-559. | | 0 |
| 77 | Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study. World Journal of Urology, 0, , . | 1.2 | 3 |
| 80 | Neoadjuvant and Adjuvant Chemotherapy for Variant Histology Bladder Cancers: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 0, 12, . | 1.3 | 1 |
| 81 | Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors. Urologic Oncology: Seminars and Original Investigations, 2022, , . | 0.8 | 0 |
| 82 | Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder. Current Opinion in Urology, 0, Publish Ahead of Print, . | 0.9 | 4 |
| 83 | The increasing indications of FDG-PET/CT in the staging and management of Invasive Bladder Cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 434-441. | 0.8 | 4 |
| 84 | Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation. International Journal of Molecular Sciences, 2022, 23, 7844. | 1.8 | 3 |
| 85 | Active surveillance for non-muscle-invasive bladder cancer: fallacy or opportunity?. Current Opinion in Urology, 0, Publish Ahead of Print, . | 0.9 | 1 |
| 86 | Guideline on trimodal therapy of bladder cancer (Nevskiy consensus 2021). Onkourologiya, 2022, 18, 142-163. | 0.1 | 0 |
| 87 | Medical gas plasma augments bladder cancer cell toxicity in preclinical models and patient-derived tumor tissues. Journal of Advanced Research, 2023, 47, 209-223. | 4.4 | 8 |
| 88 | Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now. Current Treatment Options in Oncology, 2022, 23, 1269-1287. | 1.3 | 10 |
| 89 | Reasons for lack of treatment in patients with locally advanced, unresectable or metastatic urothelial carcinoma. Acta Oncol ³ gica, 2022, 61, 1036-1042. | 0.8 | 2 |
| 90 | High-Grade Urothelial Carcinoma with Squamous Differentiation and Favourable Response to Immunotherapy â€“ a Case Report. Journal of Medical & Radiation Oncology, 2022, 2, 57-61. | 0.0 | 0 |
| 91 | Construction and verification of a novel hypoxia-related lncRNA signature related with survival outcomes and immune microenvironment of bladder urothelial carcinoma by weighted gene co-expression network analysis. Frontiers in Genetics, 0, 13, . | 1.1 | 2 |
| 92 | Effects of Nursing Care for the Treatment of Patients with Bladder Cancer: A Systematic Review and Meta-analysis. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-9. | 0.7 | 2 |
| 93 | Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet, The, 2022, 400, 1712-1721. | 6.3 | 67 |
| 94 | Radical cystectomy in non-metastatic sarcomatoid bladder cancer: A direct comparison vs urothelial bladder cancer. European Journal of Surgical Oncology, 2023, 49, 271-277. | 0.5 | 2 |
| 95 | Decreased Preoperative Serum AGR as a Diagnostic Marker of Poor Prognosis after Radical Surgery of Upper Urinary Tract and Bladder Cancers from a Pooled Analysis of 9,002 Patients. Disease Markers, 2022, 2022, 1-12. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 96 | Porcine Bladder Replacement with a Bilayer Silk Fibroin Enhanced Prosthetic Reservoir: A Feasibility Study. <i>Journal of Endourology</i> , 0, . | 1.1 | 0 |
| 97 | A novel signature to predict the neoadjuvant chemotherapy response of bladder carcinoma: Results from a territory multicenter real-world study. <i>Frontiers in Genetics</i> , 0, 13, . | 1.1 | 0 |
| 98 | French AFU Cancer Committee Guidelines“Update 2022”2024: Muscle-Invasive Bladder Cancer (MIBC). <i>Progres En Urologie</i> , 2022, 32, 1141-1163. | 0.3 | 4 |
| 100 | Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy. <i>Urologia Internationalis</i> , 2023, 107, 239-245. | 0.6 | 1 |
| 102 | Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: A nationwide cohort study. <i>Radiotherapy and Oncology</i> , 2023, 183, 109584. | 0.3 | 1 |
| 103 | Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 1560. | 1.0 | 2 |
| 104 | Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations. <i>Cancers</i> , 2023, 15, 1323. | 1.7 | 1 |
| 105 | Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial. <i>Cancers</i> , 2023, 15, 1742. | 1.7 | 4 |
| 106 | Implications for diagnosis and treatment strategies in non-muscle invasive bladder cancer with variant histology: a systematic review. <i>Minerva Urology and Nephrology</i> , 2023, 75, . | 1.3 | 2 |
| 107 | PET Imaging in Bladder Cancer: An Update and Future Direction. <i>Pharmaceuticals</i> , 2023, 16, 606. | 1.7 | 0 |
| 108 | Association of patient-reported pain with survival in bladder cancer: a post-hoc analysis of the iBLAD trial. <i>Acta Oncol“gica</i> , 2023, 62, 814-819. | 0.8 | 1 |
| 109 | Prevalence of metabolic acidosis in ileal diversions more than one year after radical cystectomy and associated secondary metabolic effects. <i>Actas Urol“gicas Espa“olas (English Edition)</i> , 2023, 47, 494-502. | 0.2 | 0 |